The Michael J. Fox Foundation for Parkinson’s Research Joins Multinational Critical Path for Parkinson’s Consortium

Consortium, led by Parkinson’s UK and the Critical Path Institute, aggregates and analyzes study data to develop a model for quantitative characterization of Parkinson’s progression.  This asset would enrich the design of trials for novel therapies. The Consortium will work with international regulators for acceptance of a quantitative model to streamline review processes.Continue reading

Genentech and Ventana Get FDA Approval on Treatment for Bladder Cancer

The U.S. Food and Drug Administration  approved Tecentriq (atezolizumab) on May 18, 2018 to treat the most common type of bladder cancer, called urothelial carcinoma. This is the first product in its class (PD-1/PD-L1 inhibitors) approved to treat this type of cancer.

FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients’ tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq..

Continue reading